Palladia Tablets

Palladia Tablets
10mg, Single Tablets - Single tablets (Blue
10mg, 30 Tablets - 30 tablets (Blue)
15mg, Single Tablets - Single tablets (Orange)
15mg, 30 Tablets - 30 tablets (Orange)
50mg, Single Tablets - Single tablets (Brown)
50mg, 30 Tablets - 30 tablets (Brown)
SKU : 10510_-RX
Price: $6.46
Price: $6.46
Save 20% on your first Autoship order
+ Save on each recurring order!

Tumor treatment medication

Veterinarian Prescription (Rx) Required
Free Shipping on orders over $75

  • Toceranib Phosphate Tablets
  • 30 count tablets
  • Used to treat mast cell tumors in dogs

*Manufacturer restricts additional discounts on this item unless explicitly specified

How to Order Prescriptions

Description

Palladia Tablets are indicated for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs only. This medication uses toceranic phosphate to combat the effects of these recurrent tumors and works on both tumors with and without regional lymph node involvement. Palladia can also be used as an alternative to chemotherapy for other various types of tumors, including melanomas, thyroid carcinomas, and more.

Dosage and Administration

Always refer to Client Information Sheet with prescription and discuss with your veterinarian. Administer an initial dosage of 3.25 mg/kg (1.48 mg/lb) body weight, orally every other day (see Table 1 in Product Label Tab). Dose reductions of 0.5 mg/kg (to a minimum dose of 2.2 mg/kg (1.0 mg/lb) every other day) and dose interruptions (cessation of PALLADIA for up to two weeks) may be utilized, if needed, to manage adverse reactions (see Table 2 as well as Warnings and Precautions). Adjust dose based on approximately weekly veterinary assessments for the first 6 weeks and approximately every 6 weeks, thereafter. PALLADIA may be administered with or without food. Do not split tablets. See Product Label Tab for more detailed information.

 

Dosage Table

Dog Body Weight

Number Of Tablets

Pounds

Kilograms 

11.0 - 11.8

5.0 - 5.3

11.9 - 15.2

5.4 - 6.9

15.3 - 18.5

7.0 - 8.4

18.6 - 22.0

8.5 - 10.0

22.1 - 25.4

10.1 - 11.5

25.5 - 28.7

11.6 - 13.0

28.8 - 32.2

13.1 - 14.6

32.3 - 35.5

14.7 - 16.1

35.6 - 38.8

16.2 - 17.6

38.9 - 42.3

17.7 - 19.2

42.4 - 45.6

19.3 - 20.7

45.7 - 50.7

20.8 - 23.0

50.8 - 59.3

23.1 - 26.9

59.4 - 65.9

27.0 - 29.9

66.0 - 71.2

30.0 - 32. 3

71.3 - 76.3

32.4 - 34.6

76.4 - 79.6

34.7 - 36.1

79.7 - 84.7

36.2 - 38.4

84.8 - 94.8

38.5 - 43.0

94.9 -105.0

43.1 - 47.6

105.1 - 110.0

47.7 - 49.9

110.1 - 113.5

50.0 -51.5

113.6 - 118.6

51.6 - 53.8

118.7 - 128.8

53.9 - 58.4

128.9 - 138.9

58.5 - 63.0

139.0 - 144.0

63.1 - 65.3

144.1 - 157.6

65.4 - 71.5

157.7 - 173.1

71.6 - 78.5

173.2 - 177.9

78.6 - 80.7

178.0 - 191.6

80.8 - 86.9

191.7 - 220.5

87.0 - 100.0

Dose

15 mg

20 mg

25 mg

30 mg

35 mg

40 mg

45 mg

50 mg

55 mg

60 mg

65 mg

70 mg

80 mg

95 mg

100 mg

110 mg

115 mg

120 mg

130 mg

150 mg

160 mg

165 mg

170 mg

180 mg

200 mg

210 mg

215 mg

250 mg

260 mg

265 mg

300 mg

10 mg

15 mg

50 mg

 

1

 

2

 

 

1

1

 

 

2

 

2

1

 

1

2

 

 

3

 

 

 

1

1

3

 

1

 

1

 

1

1

2

 

1

 

2

1

 

3

1

 

 

2

1

 

2

 

1

2

2

 

2

 

2

2

 

 

3

1

 

3

 

1

3

2

 

3

 

2

3

 

4

1

4

 

1

4

 

5

1

 

5

 

1

5

 

 

6


Storage Directions

Store at controlled room temperature 20° to 25° C (68° to 77° F). Keep away from children and pets.

 

Contraindications

Do not use in dogs used for breeding, or for pregnant or lactating bitches (see Clinical Pharmacology).

Warnings

Palladia may cause vascular dysfunction which can lead to edema and thromboembolism, including pulmonary thromboembolism. Discontinue drug until clinical signs and clinical pathology have normalized. To assure vasculature homeostasis, wait at least 3 days after stopping drug before performing surgery (see Adverse Reactions). Serious and sometimes fatal gastrointestinal complications including gastrointestinal perforation have occurred rarely in dogs treated with PALLADIA (see Adverse Reactions). If gastrointestinal ulceration is suspected, stop drug administration and treat appropriately.

Human Warnings

NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Children should not come in contact with PALLADIA. Keep children away from feces, urine, or vomit of treated dogs. To avoid exposure to drug, wash hands with soap and water after administering PALLADIA and wear protective gloves to prevent direct contact with feces, urine, vomit, and broken or moistened PALLADIA tablets. Place all waste materials in a plastic bag and seal before general disposal. If eyes are accidentally exposed to the drug, rinse eyes with water immediately. In case of accidental ingestion by a person, seek medical advice immediately, show the package insert or label to the physician. Gastrointestinal discomfort such as vomiting or diarrhea may occur if this drug is accidentally ingested. Pregnant women, women who may become pregnant, or nursing mothers should pay special attention to these handling precautions. (See handling instructions above.) PALLADIA, like other drugs in its class, prevents the formation of new blood vessels in tumors. In a similar manner, PALLADIA may affect blood vessel formation in the developing fetus and may harm an unborn baby (cause birth defects). For pregnant women, accidental ingestion of PALLADIA may have adverse effects on pregnancy.
Customer Reviews
(0.00)
# of Ratings: 0
RX required for this item.
Click here for our full Prescription Policy and Form

Palladia Tablets
  • Antineoplastic
  • For oral use in dogs only
  • Antiproliferative and antiandiogenic agent used to treat Patnaik grade II or III, cutaneous mast cell tumors in dogs.
  • This medication uses toceranic phosphate to combat the effects of these recurrent tumors and works on both tumors with and without regional lymph node involvement.
  • Can also be used as an alternative to chemotherapy for other various types of tumors, including melanomas, thyroid carcinomas, and more.

Dosage and Administration

  • Always refer to Client Information Sheet with prescription and discuss with your veterinarian.
  • Administer an initial dosage of 3.25 mg/kg (1.48 mg/lb) body weight, orally every other day (see Table 1 in Product Label Tab).
  • Dose reductions of 0.5 mg/kg (to a minimum dose of 2.2 mg/kg (1.0 mg/lb) every other day) and dose interruptions (cessation of PALLADIA for up to two weeks) may be utilized, if needed, to manage adverse reactions (see Table 2 as well as Warnings and Precautions).
  • Adjust dose based on approximately weekly veterinary assessments for the first 6 weeks and approximately every 6 weeks, thereafter.
  • PALLADIA may be administered with or without food.
  • Do not split tablets.

See Product Label Tab for more detailed information.

Loading...